The Pfizer logo on a company facility.
Image: © cbies/Stock.adobe.com

Pfizer to invest €1.2bn in Dublin and hire for hundreds of jobs

1 Dec 2022

The company plans to hire for up to 500 roles, bringing its total headcount in Ireland to around 5,500.

Pharma giant Pfizer is embarking on a massive hiring spree as it makes a €1.2bn investment at its Grange Castle manufacturing site in Dublin.

This is company’s biggest expansion investment in Ireland to date. There will be 400 to 500 jobs added, bringing Pfizer’s total headcount in the country to approximately 5,500.

The funding injection will provide for a new facility built on the site premises at Grange Castle. Due for completion in 2027, this facility will double the capacity for biological drug substance manufacturing at the site.

The investment will ensure that Pfizer has capacity for licensed and pipeline products in oncology, rare disease, inflammation and immunology and internal medicines.

Pfizer made a €40m investment at the site last year and created 75 new jobs when the Grange Castle facility was brought onto the company’s global Covid-19 manufacturing network.

Pfizer’s other Irish manufacturing sites are in Newbridge, Co Kildare, and Ringaskiddy, Co Cork. These manufacture medicines and vaccines for conditions such as arthritis, inflammation, cancer, haemophilia, pain and stroke.

The company’s total investment to date in Ireland now stands in excess of $9bn.

Taoiseach Micheál Martin, TD, said the latest expansion news is “a considerable vote of confidence in the talent of our workforce and our economy”.

“Pfizer has played an instrumental role during the pandemic. It is pleasing to see just how much scientific progress has been made over the last number of years, and I have no doubt that Ireland will continue to be at the forefront of scientific innovation.”

Mike McDermott, chief global supply officer and executive VP at Pfizer, said the move “significantly strengthens” the pharma company’s operations in Ireland.

“Grange Castle has played a critical role in our global Covid-19 vaccine network, and this investment for non-Covid licensed and pipeline products will help to further expand the site’s broad and robust capabilities.”

More information on working at Pfizer is available on its website.

10 things you need to know direct to your inbox every weekday. Sign up for the Daily Brief, Silicon Republic’s digest of essential sci-tech news.

Blathnaid O’Dea
By Blathnaid O’Dea

Blathnaid O’Dea worked as a Careers reporter until 2024, coming from a background in the Humanities. She likes people, pranking, pictures of puffins – and apparently alliteration.

Loading now, one moment please! Loading